SEC Form 4 · accession 0001179110-17-014593

AbbVie Inc. · ABBV

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chairman of the Board and CEO · Director

Period of report

Nov 21, 2017

Accepted (ET)

Nov 24, 2017 · 4:55 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001551152

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common stock, $0.01 par value	Nov 21, 2017	M	218,193	$58.88	A	492,030	D
Common stock, $0.01 par value^F1	Nov 21, 2017	S	218,193	$94.0076	D	273,837	D
Common stock, $0.01 par value^F2	holding	—	—		—	4,600	I	By spouse
Common stock, $0.01 par value^F2	holding	—	—		—	450	I	By step-daughter
Common stock, $0.01 par value^F2	holding	—	—		—	450	I	By step-son

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option (right to buy)^F3	$58.88	Nov 21, 2017	M	218,193	D	Feb 19, 2017	Feb 18, 2025	Common stock, $0.01 par value	218,193	109,097	D

F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.75 to $94.34, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2The reporting person disclaims beneficial ownership of these securities.
F3Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).